PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v8i3.7232ArticleA Case of Waldenström Macroglobulinemia with Acute Kidney Injury as the First Manifestation and Literature Reviewhttps://artdesignp.com/journal/PAR/8/3/10.26689/par.v8i3.7232XuYang,GuoShanshan,GouYanli,ZhengXijie2024832024-06-19Waldenström macroglobulinemia is a rare lymphoid tumor accounting for 2% of all hematological malignancies. Renal complications are less common compared to multiple myeloma, with the most frequent renal manifestations being microproteinuria and microhematuria. This paper presents a case of Waldenström macroglobulinemia with acute kidney injury as the initial manifestation. A 75-year-old male was admitted to the Affiliated Hospital of Hebei University after elevated blood creatinine levels were detected for one day. Upon admission, his blood creatinine was 255 µmol/L, urine protein was 1+, urine erythrocytes were negative, electrophoresis showed IgM positivity in the κ-region, and a bone marrow biopsy indicated a tendency towards lymphoplasmacytic lymphoma. The patient was discharged after receiving a treatment regimen of prednisone acetate, thalidomide, and cyclophosphamide, and continued oral medication outside the hospital. The patient returned two weeks later due to diarrhea and was found to have a blood creatinine level of 985 µmol/L, along with severe acidosis and hyperkalemia. The patient refused renal replacement therapy and was not followed up, resulting in a poor prognosis. Additionally, a review of the literature is provided to contextualize this case within the broader scope of existing research.

Salviani C, Guido G, Serriello I, et al., 2014, Renal Involvement in Waldenström’s Macroglobulinemia: Case Report and Review of Literature. Ren Fail, 36(1): 114–118. https://doi.org/10.3109/0886022X.2013.832859

Ghafoor B, Masthan SS, Hameed M, et al., 2024, Waldenström Macroglobulinemia: A Review of Pathogenesis, Current Treatment, and Future Prospects. Ann Hematol, 103(6): 1859–1876. https://doi.org/10.1007/s00277-023-05345-9

Vos JM, Gustine J, Rennke HG, et al., 2016, Renal Disease Related to Waldenström Macroglobulinaemia: Incidence, Pathology and Clinical Outcomes. Br J Haematol. 175(4): 623–630. https://doi.org/10.1111/bjh.14279

Yonemura K, Suzuki T, Sano K, et al., 2000, A Case with Acute Renal Failure Complicated by Waldenström’s Macroglobulinemia and Cryoglobulinemia. Ren Fail, 22(4): 511–515. https://doi.org/10.1081/jdi-100100892

Argani I, Kipkie GF, 1964, Macroglobulinemic Nephropathy. Acute Renal Failure in Macroglobulinemia of Waldenstroem. Am J Med, 36: 151–157. https://doi.org/10.1016/0002-9343(64)90157-3

Uppal NN, Monga D, Vernace MA, et al., 2019, Kidney Diseases Associated with Waldenström Macroglobulinemia. Nephrol Dial Transplant, 34(10): 1644–1652. https://doi.org/10.1093/ndt/gfy320

Ravi G, Kapoor P, 2022, Current Approach to Waldenström Macroglobulinemia. Cancer Treat Res Commun, 31: 100527. https://doi.org/10.1016/j.ctarc.2022.100527

Zanwar S, Abeykoon JP, Ansell SM, et al., 2018, Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. Blood, 132(Suppl 1): 4152. https://doi.org/10.1182/blood-2018-99-119849

Higgins L, Nasr SH, Said SM, et al., 2018, Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. Clin J Am Soc Nephrol, 13(7): 1037–1046. https://doi.org/10.2215/CJN.13041117

Treon SP, Meid K, Tripsas C, et al., 2017, Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res, 23(10): 2400–2404. https://doi.org/10.1158/1078-0432.CCR-16-1918